Clinical Trial Update: A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety trial of Crisaborole ointment 2% in Japanese participants with mild to moderate atopic dermatitis was terminated with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Crisaborole Ointment (2%) (crisaborole)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Phase 3 | Status: TERMINATED | Results posted: 2021-08-12